Tag Archives: New England Journal of Medicine

October, 2017

  • 6 October

    Bluebird Gene Therapy Halts Progression of Cerebral Adrenoleukodystrophy

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating Lenti-D™ investigational …

April, 2017

March, 2017

March, 2016

January, 2016

  • 27 January

    Cost and Value

    Where does the true value of cancer treatment lie? Oncology experts grapple with this important question, with one of the more recent people to chime in being Robert C. Young, M.D., of RCY Medicine in Philadelphia, in an essay in a recent issue of the New England Journal of Medicine. Dr. …

  • 15 January

    Long-Term Survivors of Childhood Cancer Living Longer Partly Due to Treatment Changes

    Memphis, Tennessee, January 13, 2016–Evidence from the Childhood Cancer Survivor Study (CCSS) suggests that changes in childhood cancer treatment and follow-up care have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which …